Australian Clinical Labs

ACL: Share Buyback And Acquisition Plans Will Drive Strong Shareholder Returns

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Feb 25

Updated

30 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-18.5%

7D

0%

Loading

1Y

-18.5%

7D

0%

You can edit this narrative until Dec 1 11:10 PM. Then, changes will post as Updates.

Author's Valuation

AU$3.417.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 30 Nov 25

ACL: Share Buyback Program Will Drive Shareholder Value Over The Next Year

Analysts have reaffirmed their price target for Australian Clinical Labs at $3.40, citing stable financial forecasts and consistent assumptions for discount rate, revenue growth, profit margin, and future price-earnings ratio. What's in the News The Board of Directors authorized a buyback plan on October 23, 2025 (Key Developments).

Shared on 16 Nov 25

ACL: Share Buyback Plan And Acquisitions Will Drive Future Upside

Analysts have maintained their price target for Australian Clinical Labs at $3.40. They cite steady expectations for profit margins and revenue growth, even with a slight increase in the discount rate.

Shared on 02 Nov 25

Analysts have revised their price target for Australian Clinical Labs slightly downward to $3.40. This adjustment is due to marginally lower expectations for revenue growth and future earnings multiples.

Shared on 18 Oct 25

Fair value Decreased 5.56%

Analysts have lowered their price target for Australian Clinical Labs from $3.60 to $3.40. They cite adjustments to their revenue growth forecasts and a slightly higher discount rate in their valuation model.

Shared on 01 May 25

Fair value Decreased 3.49%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 0.54%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 1.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 0.53%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 1.07%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

AU$3.4

17.1% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

4.20%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.67%

Calculation

AU$46.00m

Earnings '28

x

16.24x

PE Ratio '28

=

AU$746.90m

Market Cap '28

AU$746.90m

Market Cap '28

/

181.12m

No. shares '28

=

AU$4.12

Share Price '28

AU$4.12 Share Price '28

Discounted to 2025 @ 6.67% p.a.

=

AU$3.40

Fair Value '25